Delcath Systems Inc (DCTH)

$12.87 -0.14 (-1.08%)
Market Cap 449.13M
Revenue (ttm) 85.23M
Net Income (ttm) 2.70M
EPS (ttm) N/A
PE Ratio 1,352.00
Forward PE N/A
Profit Margin 3.17%
Debt to Equity Ratio 0.00
Volume 389,000
Avg Vol 520,534
Day's Range N/A - N/A
Shares Out 34.52M
Stochastic %K 32%
Beta 0.49
Analysts Strong Sell
Price Target $22.40

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices
Sector: Healthcare
Phone: 212 489 2100
Fax: 212 489 2102
Address:
566 Queensbury Avenue, Queensbury, United States
xcdvfxcvnbxxvsd
xcdvfxcvnbxxvsd Jul. 14 at 3:48 PM
$DCTH Nice article by Moffit https://www.moffitt.org/endeavor/archive/moffitt-completes-100th-percutaneous-hepatic-perfusion-since-fda-approval/
0 · Reply
xcdvfxcvnbxxvsd
xcdvfxcvnbxxvsd Jul. 14 at 2:31 PM
$DCTH Sutter Health now listed as 31st active REMS HEPZATO site
0 · Reply
alexpitti
alexpitti Jul. 14 at 3:47 AM
the shorts are running away from $DCTH
0 · Reply
brunoq14
brunoq14 Jul. 14 at 12:11 AM
$DCTH BTIG today raised the price target from $16 to $17.
1 · Reply
BioTuesdays
BioTuesdays Jul. 9 at 5:55 PM
$DCTH has announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy, in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care treatment for liver-dominant metastatic breast cancer (mBC). https://biotuesdays.com/2026/07/09/first-patient-dosed-in-delcaths-global-trial-of-hepzato-in-mbc/
0 · Reply
WhaleTracker_
WhaleTracker_ Jul. 9 at 3:54 PM
$DCTH Another interesting setup showing why price action matters. Different sectors, different stories, but the same trading principle keeps appearing: respect the levels, watch the structure, and let the chart confirm the move. $DCTH has been following the technical setup closely, with buyers stepping in at key areas and momentum continuing to develop. This is why I focus on process over predictions. Good setups can appear anywhere when you understand trend, support, and momentum. The market always creates opportunities. The goal is being ready when they show up.
0 · Reply
prismmarketview
prismmarketview Jul. 9 at 2:40 PM
$DCTH first patient dosed in Phase 2 HEPZATO trial for liver-dominant HER2-negative metastatic breast cancer. This is Delcath’s shot to show HEPZATO is a platform, not a single-indication play. Watching data and timelines closely. #DCTH #Biotech #Oncology #HEPZATO https://prismmarketview.com/delcath-systems-starts-phase-2-hepzato-trial-in-liver-dominant-metastatic-breast-cancer/
0 · Reply
brunoq14
brunoq14 Jul. 9 at 2:05 PM
$DCTH This is exactly how my mother died. Breast cancer followed by liver cancer. Good luck to Delcath.
1 · Reply
Playthegame06
Playthegame06 Jul. 9 at 1:38 PM
$DCTH Alex - Do you know if a drug company pays the trial sites for participating?
1 · Reply
brunoq14
brunoq14 Jul. 9 at 1:21 PM
$DCTH https://www.businesswire.com/news/home/20260709141093/en/
1 · Reply
Latest News on DCTH
Delcath Systems price target raised to $17 from $16 at BTIG

2026-07-13T11:20:52.000Z - 1 day ago

Delcath Systems price target raised to $17 from $16 at BTIG

Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer

2026-07-09T12:05:51.000Z - 5 days ago

Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Jul 9, 2026, 8:00 AM EDT - 5 days ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

2026-05-26T20:05:59.000Z - 6 weeks ago

Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

May 26, 2026, 4:01 PM EDT - 6 weeks ago

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 4:01 PM EDT - 2 months ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 8:00 AM EDT - 2 months ago

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems presents new data on M-PHP at ESMO

2026-05-07T14:11:04.000Z - 2 months ago

Delcath Systems presents new data on M-PHP at ESMO

Delcath Systems reports Q1 EPS (3c), consensus (9c)

2026-05-07T13:35:47.000Z - 2 months ago

Delcath Systems reports Q1 EPS (3c), consensus (9c)

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

2026-05-07T13:34:32.000Z - 2 months ago

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

Delcath Systems Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems Earnings Call Transcript: Q1 2026

Delcath Systems Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems Earnings release: Q1 2026

Delcath Systems Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems Quarterly report: Q1 2026

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

May 7, 2026, 8:00 AM EDT - 2 months ago

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Apr 23, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Apr 6, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems management to meet with Craig Hallum

2026-04-02T14:44:15.000Z - 3 months ago

Delcath Systems management to meet with Craig Hallum

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems Proxy statement: Proxy filing

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems Proxy statement: Proxy filing

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Apr 1, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

2026-03-03T13:43:26.000Z - 4 months ago

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Mar 3, 2026, 8:00 AM EST - 4 months ago

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems price target lowered to $27 from $29 at Clear Street

2026-02-26T18:26:15.000Z - 4 months ago

Delcath Systems price target lowered to $27 from $29 at Clear Street

Delcath Systems reports Q4 EPS (5c), consensus (3c)

2026-02-26T13:33:50.000Z - 4 months ago

Delcath Systems reports Q4 EPS (5c), consensus (3c)

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

2026-02-26T13:33:07.000Z - 4 months ago

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

Delcath Systems Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Earnings Call Transcript: Q4 2025

Delcath Systems Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Annual report: Q4 2025

Delcath Systems Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Earnings release: Q4 2025

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 26, 2026, 8:00 AM EST - 4 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Feb 12, 2026, 8:00 AM EST - 5 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 27, 2026, 8:05 AM EST - 6 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems price target raised to $29 from $28 at Clear Street

2026-01-09T15:30:16.000Z - 6 months ago

Delcath Systems price target raised to $29 from $28 at Clear Street

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

2026-01-09T13:15:29.000Z - 6 months ago

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 9, 2026, 8:05 AM EST - 6 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Delcath Systems publishes results from subgroup analyses of FOCUS study

2025-12-31T13:15:08.000Z - 6 months ago

Delcath Systems publishes results from subgroup analyses of FOCUS study

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 31, 2025, 8:00 AM EST - 6 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Delcath Systems announces publication of CHEMOSAT study

2025-12-03T21:05:29.000Z - 7 months ago

Delcath Systems announces publication of CHEMOSAT study

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 7 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems authorizes $25M buyback program

2025-11-20T21:05:49.000Z - 8 months ago

Delcath Systems authorizes $25M buyback program

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 20, 2025, 4:01 PM EST - 8 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Delcath Systems publishes review of Hepzato Kit

2025-11-18T14:38:40.000Z - 8 months ago

Delcath Systems publishes review of Hepzato Kit

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 18, 2025, 8:00 AM EST - 8 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Delcath announces publication supporting early use of liver-directed therapy

2025-11-13T14:21:28.000Z - 8 months ago

Delcath announces publication supporting early use of liver-directed therapy

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 13, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 6, 2025, 4:01 PM EST - 8 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Earnings Call Transcript: Q3 2025

Delcath Systems Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Quarterly report: Q3 2025

Delcath Systems Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Earnings release: Q3 2025

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Nov 4, 2025, 8:00 AM EST - 9 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 21, 2025, 8:30 AM EDT - 9 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Delcath Systems Transcript: Study Result

Oct 20, 2025, 8:45 AM EDT - 9 months ago

Delcath Systems Transcript: Study Result

Delcath Systems Press release: Study Result

Oct 20, 2025, 8:45 AM EDT - 9 months ago

Delcath Systems Press release: Study Result

Delcath Systems Slides: Corporate Presentation

Oct 20, 2025, 7:00 AM EDT - 9 months ago

Delcath Systems Slides: Corporate Presentation

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:15 PM EDT - 9 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Oct 18, 2025, 4:13 PM EDT - 9 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 22, 2025, 4:01 PM EDT - 10 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 11:00 AM EDT - 10 months ago

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 19, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q2 2025

Delcath Systems Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q2 2025

Delcath Systems Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q2 2025

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jul 23, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Delcath Systems Slides: Investor Presentation

May 22, 2025, 10:00 AM EDT - 1 year ago

Delcath Systems Slides: Investor Presentation

Delcath Systems Issues Full Year 2025 Guidance

May 22, 2025, 7:00 AM EDT - 1 year ago

Delcath Systems Issues Full Year 2025 Guidance

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 15, 2025, 4:30 PM EDT - 1 year ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 5:30 PM EDT - 1 year ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q1 2025

Delcath Systems Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q1 2025

Delcath Systems Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q1 2025

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

May 8, 2025, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q4 2024

Delcath Systems Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Annual report: Q4 2024

Delcath Systems Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q4 2024

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q3 2024

Delcath Systems Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Quarterly report: Q3 2024

Delcath Systems Earnings release: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q3 2024

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Nov 8, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

xcdvfxcvnbxxvsd
xcdvfxcvnbxxvsd Jul. 14 at 3:48 PM
$DCTH Nice article by Moffit https://www.moffitt.org/endeavor/archive/moffitt-completes-100th-percutaneous-hepatic-perfusion-since-fda-approval/
0 · Reply
xcdvfxcvnbxxvsd
xcdvfxcvnbxxvsd Jul. 14 at 2:31 PM
$DCTH Sutter Health now listed as 31st active REMS HEPZATO site
0 · Reply
alexpitti
alexpitti Jul. 14 at 3:47 AM
the shorts are running away from $DCTH
0 · Reply
brunoq14
brunoq14 Jul. 14 at 12:11 AM
$DCTH BTIG today raised the price target from $16 to $17.
1 · Reply
BioTuesdays
BioTuesdays Jul. 9 at 5:55 PM
$DCTH has announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy, in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care treatment for liver-dominant metastatic breast cancer (mBC). https://biotuesdays.com/2026/07/09/first-patient-dosed-in-delcaths-global-trial-of-hepzato-in-mbc/
0 · Reply
WhaleTracker_
WhaleTracker_ Jul. 9 at 3:54 PM
$DCTH Another interesting setup showing why price action matters. Different sectors, different stories, but the same trading principle keeps appearing: respect the levels, watch the structure, and let the chart confirm the move. $DCTH has been following the technical setup closely, with buyers stepping in at key areas and momentum continuing to develop. This is why I focus on process over predictions. Good setups can appear anywhere when you understand trend, support, and momentum. The market always creates opportunities. The goal is being ready when they show up.
0 · Reply
prismmarketview
prismmarketview Jul. 9 at 2:40 PM
$DCTH first patient dosed in Phase 2 HEPZATO trial for liver-dominant HER2-negative metastatic breast cancer. This is Delcath’s shot to show HEPZATO is a platform, not a single-indication play. Watching data and timelines closely. #DCTH #Biotech #Oncology #HEPZATO https://prismmarketview.com/delcath-systems-starts-phase-2-hepzato-trial-in-liver-dominant-metastatic-breast-cancer/
0 · Reply
brunoq14
brunoq14 Jul. 9 at 2:05 PM
$DCTH This is exactly how my mother died. Breast cancer followed by liver cancer. Good luck to Delcath.
1 · Reply
Playthegame06
Playthegame06 Jul. 9 at 1:38 PM
$DCTH Alex - Do you know if a drug company pays the trial sites for participating?
1 · Reply
brunoq14
brunoq14 Jul. 9 at 1:21 PM
$DCTH https://www.businesswire.com/news/home/20260709141093/en/
1 · Reply
alexpitti
alexpitti Jul. 7 at 8:46 PM
i sold my adobe thankfully. trading is always stressful. back to the ole barn with my long term holds in $STXS $ABEO $DCTH $MIST
1 · Reply
PolycarpFX
PolycarpFX Jul. 7 at 2:34 AM
$DCTH
1 · Reply
BillionerOfKing
BillionerOfKing Jul. 6 at 11:18 PM
$DCTH Current Stock Price: $13.49 Contracts to trade: $12.5 DCTH Jul 17 2026 Call Entry: $0.30 Exit: $0.46 ROI: 52% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Playthegame06
Playthegame06 Jul. 6 at 6:06 PM
$DCTH
0 · Reply
actuallysam
actuallysam Jul. 6 at 3:01 PM
$DCTH quiet on the message board, good price, that is about it
1 · Reply
Doozio
Doozio Jul. 4 at 9:38 PM
$DCTH ENTA 🐒🍌🧠⏰♾️
0 · Reply
alexpitti
alexpitti Jul. 2 at 10:22 PM
happy 4th of july $STXS $DCTH $ABEO $ADBE $MIST
3 · Reply
mar99
mar99 Jul. 2 at 8:01 PM
$DCTH It was just 2 weeks ago Dcth was fighting to finally close over 12 as everyday it went over 12 and they took it back down until finally closing over 12. Now less than 2 weeks later after several tries over 13 we close over 13 and we are closing in on 52 week high from August. Nice to see the way this is progressing and nice way to go into the long weekend.
1 · Reply
Playthegame06
Playthegame06 Jun. 30 at 12:52 AM
$DCTH Last day of 2 Qtr......Let's hope and pray Revs are north of $25MM.
2 · Reply
Stocks_and_Stacks
Stocks_and_Stacks Jun. 27 at 3:04 PM
$DCTH 📚 Why $DCTH is a high-conviction play right now: Delcath is commercializing HEPZATO KIT, a breakthrough liver-directed chemotherapy system for unresectable hepatic metastases (ocular melanoma and beyond). FY2026 revenue guidance is at least $100M with strong procedure growth and expanding adoption. Recent clinical data and ASCO updates continue to build the case. Big Name Institutional Buyers: Rosalind Advisors, BlackRock, Vanguard, Bank of America, and other institutions own over 50% of the company with ongoing accumulation. Wanna know more hit that follow button 🤝
0 · Reply
alexpitti
alexpitti Jun. 26 at 11:54 PM
$DCTH nothing is up. if you look at the volume numbers, $SI $STXS $ABEO all had way above normal volume
2 · Reply
CosmicMiner
CosmicMiner Jun. 26 at 8:08 PM
$DCTH up 5% today. Tracking the price action and volume on this move.
0 · Reply